Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > REGULATORY
REGULATORY
- Post-Launch Re-Pricing Likely the Focus of Chuikyo Leqembi Discussions
October 5, 2023
- WHO Recommends Takeda’s Dengue Vaccine in Children Ages 6-16
October 4, 2023
- MHLW Set to Wrap Up Drug Copay Debate by Year-End: Minister
October 4, 2023
- NHO Data Now Available through PMDA’s MID-NET Database
October 3, 2023
- As Copay Debate Picks Up Steam, MHLW Floats 4 Ideas for Coverage Reform
October 2, 2023
- Japan Seeking Solutions as Lab Monkey Shortage, Price Surge Threaten to Stymie Drug Development
October 2, 2023
- MHLW Proposes Setting Key Drugs as Category Separated from Bundled Trades
September 29, 2023
- Guidelines Should Urge Drug Makers to Explain Solo-Wholesaler Decisions: Panel Members
September 29, 2023
- MHLW Expert Panel Draws Up New Cancer Research Strategy
September 28, 2023
- As Chuikyo Begins Pricing Debate of Leqembi, Panelists Urge Safety, Fair Access
September 28, 2023
- Japan PM Asks Health Minister to Reform Pricing of Potential Blockbusters
September 28, 2023
- Ex-Senior Vice Minister Koga to Lead LDP’s Health Division
September 28, 2023
- Japan Agrees to Buy Extra 10 Million Doses of Pfizer COVID Vaccine
September 27, 2023
- Kamoshita Tapped as Advisor to PM on Drug, Dementia Policies
September 27, 2023
- Aichi Case of Death After COVID Shot Could Have Been Avoided with Adequate Steps: Report
September 27, 2023
- Japan to Balance Innovation, Finances in Leqembi Pricing: Minister
September 27, 2023
- Draft Revision of Basic Blood Product Policy OK’ed, to Be Finalized by March-End
September 27, 2023
- Leqembi Approval Marks New Era of Dementia Treatment: Japan PM
September 26, 2023
- Japan Approves Multiple Firsts, Leqembi, Arexvy, Leqvio, and More
September 26, 2023
- Leqembi Subject to Cost Control Rule for Potential Big Sellers, MHLW Still Set to Meet Listing Deadline
September 26, 2023
ページ
More than a year after Dupixent (dupilumab) became the first antibody therapy approved for COPD in Japan, drug makers are…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…